Renaissance Technologies LLC Has $19.77 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Renaissance Technologies LLC cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 377,580 shares of the biopharmaceutical company’s stock after selling 53,800 shares during the quarter. Renaissance Technologies LLC owned 0.30% of Halozyme Therapeutics worth $19,770,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock valued at $490,072,000 after buying an additional 152,870 shares during the last quarter. TD Asset Management Inc lifted its holdings in shares of Halozyme Therapeutics by 28.1% during the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after buying an additional 557,350 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock valued at $99,363,000 after buying an additional 209,530 shares during the last quarter. Stephens Investment Management Group LLC lifted its holdings in shares of Halozyme Therapeutics by 4.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,518,455 shares of the biopharmaceutical company’s stock valued at $56,122,000 after buying an additional 63,748 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its holdings in shares of Halozyme Therapeutics by 23.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company’s stock valued at $58,319,000 after buying an additional 270,579 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Down 0.4 %

Shares of HALO stock opened at $59.24 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $32.83 and a 12 month high of $65.53. The firm has a market cap of $7.54 billion, a PE ratio of 24.48, a price-to-earnings-growth ratio of 0.57 and a beta of 1.28. The stock has a 50 day moving average of $58.40 and a 200-day moving average of $49.15. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The company had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. During the same period in the previous year, the company earned $0.68 earnings per share. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on HALO shares. Morgan Stanley lifted their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $48.00 to $51.00 in a report on Friday, June 7th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $52.00 to $57.00 in a report on Thursday. Benchmark reaffirmed a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Finally, The Goldman Sachs Group upped their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Insider Transactions at Halozyme Therapeutics

In other news, CFO Nicole Labrosse sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total transaction of $519,300.00. Following the completion of the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at $803,876.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares in the company, valued at $4,031,729.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Nicole Labrosse sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $51.93, for a total value of $519,300.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at $803,876.40. The disclosure for this sale can be found here. Insiders sold a total of 84,881 shares of company stock worth $4,888,184 over the last three months. 2.40% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.